| Patent Number |
Title Of Patent |
Date Issued |
| RE30293 |
Process for preparing 1,5-benzodiazepine-2-ones |
June 3, 1980 |
| 1-Aryl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-ones of the general formula ##STR1## wherein: R.sub.1 is hydrogen, or unsaturated lower alkyl, preferably of 1-3 carbons, or unsaturated lower alkyl preferably of 2-3 carbonsR.sub.2, R.sub.3, R.sub.4, R.sub.5 are the same or different |
| 6608025 |
Human NESP55 polypeptides, polynucleotides and uses thereof |
August 19, 2003 |
| A substantially pure polypeptide (human NESP55) comprising the amino acid sequenceor a variant, fragment, fusion or derivative thereof, or a fusion of a said variant or fragment or derivative, wherein the polypeptide variant has an amino acid sequence which has at least 90% identity with |
| 6074664 |
Medicament form for the delivery of collagenase to wounds and process for the preparation thereo |
June 13, 2000 |
| An administration form for the release of collagenase to wounds is characterised in that it exhibits a combination of specific properties as hereinbelow:a. it is coherent, flat-shaped and deformable;b. it has a superficial extension that is equal to or smaller than the wound surface to b |
| 5849941 |
Preparation of colloidal aqueous solutions of active substances of low solubility and a lipid th |
December 15, 1998 |
| A process for producing solutions of active substances of low solubility, which comprises (1) dissolving the active substance with a phospholipid and a water-soluble lipid in an organic solvent, (2) evaporating the resulting solution to dryness, (3) taking up the residue in a strongly |
| 5789156 |
Tetracycline-regulated transcriptional inhibitors |
August 4, 1998 |
| Nucleic acid molecules and proteins useful for regulating the expression of genes in eukaryotic cells and organisms in a highly controlled manner are disclosed. In the regulatory system of the invention, transcription of a tet operator-linked nucleotide sequence is inhibited by a transcr |
| 5432196 |
Preparation of an active substance solution which can be sterilized by filtration |
July 11, 1995 |
| A process for preparing an aqueous active substance solution which can be sterilized by filtration entails mixing anipamil hydrochloride with a phospholipid in the ratio of from 1:2 to 2:1 by weight, converting the resulting mixture into a gel by adding water at elevated temperature, and |
| 5420137 |
Amonafide salts |
May 30, 1995 |
| The monohydrochloride and the monomethanesulfonate of amonafide are described. The salts have good pharmaceutical properties besides their antitumor action. |
| 5370877 |
Method for improving delivery and reducing toxicity of biologically active substances using nove |
December 6, 1994 |
| .alpha.-Aminocarboxylic acid derivatives of the formula: ##STR1## where n, X, Y and Z have the meanings stated in the description, and their preparation are described. The compounds are used in a method for improving delivery and reducing toxicity of biologically active substances |
| 5364635 |
Solid drug form with a high verapamil content |
November 15, 1994 |
| A solid drug form containing not less than 90% by weight verapamil is produced by granulating at from 30.degree. to 55.degree. C. with a little water, drying and, where appropriate, conventional tableting or by pelleting, in which case the granules obtained as described are, after co |
| 5354561 |
Process for producing solid active substance forms and products thereof |
October 11, 1994 |
| A process is described for the production of solid forms of active substances, which forms have good redispersibility in aqueous systems, which comprises mixing PEG and dextran with water and--if phase separation occurs--removing the upper phase, dissolving an active substance in the |
| 5342853 |
Method of using nor-verapamil and nor-gallopamil as anti-arteriosclerotics |
August 30, 1994 |
| The use of nor-verapamil and nor-gallopamil and the salts thereof with physiologically tolerated acids is disclosed for the preparation of drugs with antiarteriosclerotic properties. |
| 5277903 |
Use of TNF and LT for the preparation of drugs |
January 11, 1994 |
| TNF and LT are used for the prophylaxis and therapy of effusions in body cavities. |
| 5230901 |
Sustained release tablet of a mixture of alginates and polyacrylates |
July 27, 1993 |
| A mixture of an alginate and a polyacrylate in a ratio of from 15:1 to 1:2 is suitable for the preparation of depot drug forms. |
| 5133960 |
Use of TNF and LT for the preparation of drugs |
July 28, 1992 |
| TNF and LT are used for the prophylaxis and therapy of effusions in body cavities. |
| 5132295 |
Alginate-based verapamil-containing depot drug form |
July 21, 1992 |
| An alginate-based depot drug form for which the rate of release of the active substance in vitro can be adjusted very precisely is described. |
| 5112624 |
Prevention of digestive disturbances in herbivores |
May 12, 1992 |
| A method for preventing digestive disturbances in herbivores entails supplementing their feed with adequate amounts of pancreatin which has preferably been given a neutral taste. |
| 4958046 |
Hydroxypropafenone glycerides |
September 18, 1990 |
| Hydroxypropafenone glycerides of the formula I ##STR1## where R is n-propyl or 1,1-dimethylpropyl,x is 2 or 3,y is 12, 14, 16, 18 or 20, anda and b differ from one another and are 0 or 1,as well as the stereoisomers thereof and the preparation thereof are described. The compounds are sui |
| 4925672 |
Products containing a calcium antagonist and a lipid-lowering agent |
May 15, 1990 |
| Combinations of calcium antagonists and lipid-lowering agents are suitable for controlling diseases. |
| 4914125 |
(S)-emopamil for the treatment of migraine |
April 3, 1990 |
| The use of (S)-emopamil and the salts thereof for the treatment of migraine is described. |
| 4874863 |
Bisnaphthalimides |
October 17, 1989 |
| Bisnaphthalimides of the formula I ##STR1## where X.sup.1 to X.sup.4 and R have the meanings stated in the description, and their preparation are described. The compounds are cytotoxic towards human cells in vitro. |
| 4777183 |
Use of anipamil |
October 11, 1988 |
| Anipamil and its salts with physiologically tolerated acids are used for the preparation of drugs having antiarteriosclerotic properties and in the treatment of arteriosclerosis. |
| 4239684 |
1,5'-Benzodiazepine-2-ones, pharmaceutical compositions thereof and method of use thereof |
December 16, 1980 |
| 1-Aryl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-ones of the general formula ##STR1## wherein: R.sub.1 is hydrogen, lower alkyl, preferably of 1-3 carbons, or unsaturated lower alkyl preferably of 2-3 carbonsR.sub.2, R.sub.3, R.sub.4, R.sub.5 are the same or different and are each |
| 4115432 |
Method for making basically-substituted phenylacetonitriles |
September 19, 1978 |
| A method is disclosed for making a basically-substituted phenylacetonitrile of the formula ##STR1## which comprises hydrolyzing a nitriloaldehyde acetal of the formula ##STR2## with aqueous acid to obtain a nitriloaldehyde of the formula ##STR3## and then subjecting said |
| 4108852 |
Process for preparing 1,5-benzodiazepine-2-ones |
August 22, 1978 |
| 1-Aryl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-ones of the general formula ##STR1## wherein: R.sub.1 is hydrogen, or unsaturated lower alkyl, preferably of 1-3 carbons, or unsaturated lower alkyl preferably of 2 - 3 carbonsR.sub.2, r.sub.3, r.sub.4, r.sub.5 are the same or differen |
